Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol

被引:11
作者
Angrist, B
Sanfilipo, M
Wolkin, A
机构
[1] NYU, Sch Med, New York Vet Affairs Med Ctr, Psychiat Serv, New York, NY USA
[2] NYU, Sch Med, Dept Psychiat, New York, NY USA
关键词
d-amphetamine; blood pressure; pulse rate; haloperidol;
D O I
10.1097/00002826-200105000-00004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In a series of earlier studies, an oral dose of 0.5 mg/kg d-amphetamine was administered to 81 patients with schizophrenia and eight normal control subjects. Seven more subjects with schizophrenia received placebo. Blood pressure and pulse rate were monitored before and 3 hours after drug administration. Blood pressure increased in both amphetamine groups, whereas placebo had no effect. However, pulse rate did not change in the schizophrenic group and only increased after 3 hours in normal control subjects as blood pressure began to decrease. Significant negative correlations between systolic blood pressure and pulse rate occurred at 2 and 3 hours, suggesting that the early cardiovascular response to amphetamine is an increase in blood pressure that recruits reflex control of heart rate. Eighteen of these subjects had hypertensive responses. Six subjects received 5 mg haloperidol intramuscularly, and 12 others had their blood pressure monitored until normalization. Haloperidol led to a more rapid decline of some but not all indices of blood pressure, suggesting that amphetamine-induced hypertension may have a dopaminergic component.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 20 条
[1]   PARTIAL IMPROVEMENT IN NEGATIVE SCHIZOPHRENIC SYMPTOMS AFTER AMPHETAMINE [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
CORWIN, J ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1982, 78 (02) :128-130
[2]   DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON NEGATIVE VS POSITIVE SYMPTOMS IN SCHIZOPHRENIA [J].
ANGRIST, B ;
ROTROSEN, J ;
GERSHON, S .
PSYCHOPHARMACOLOGY, 1980, 72 (01) :17-19
[3]   AMPHETAMINE RESPONSE AND RELAPSE RISK AFTER DEPOT NEUROLEPTIC DISCONTINUATION [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
WOLKIN, A ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1985, 85 (03) :277-283
[4]   RESPONSES TO APOMORPHINE, AMPHETAMINE, AND NEUROLEPTICS IN SCHIZOPHRENIC SUBJECTS [J].
ANGRIST, B ;
ROTROSEN, J ;
GERSHON, S .
PSYCHOPHARMACOLOGY, 1980, 67 (01) :31-38
[5]  
ANGRIST B, 1974, AM J PSYCHIAT, V131, P817
[6]  
ANGRIST B, 1981, RECENT ADV NEUROPSYC, V31, P49
[7]  
[Anonymous], PHARM BASIS THERAPEU
[8]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[9]  
[Anonymous], 1980, DSM 3
[10]  
BARNE RM, 1998, PHYSIOLOGY, P450